Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Regencell Bioscience Holdings Ltd
NASDAQ RGC
Data sourced from
and
and
Regencell Bioscience Holdings Ltd Cash to Debt Ratio for the year ending June 30, 2023
Regencell Bioscience Holdings Ltd Cash to Debt Ratio is NA for the year ending June 30, 2023. The cash to debt ratio assesses a company's ability to cover its total debt obligations with its available cash. It is calculated by dividing cash by total debt. This ratio indicates the company's liquidity and its capacity to meet its debt obligations using its cash reserves. A higher cash to debt ratio suggests a stronger ability to cover debts with cash resources.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: RGC
| CEO | Mr. Yat-Gai Au |
| IPO Date | July 16, 2021 |
| Location | Hong Kong |
| Headquarters | First Commercial Building, Causeway Bay, Hong Kong |
| Employees | 12 |
| Sector | Healthcare |
| Industry | Drug manufacturers - specialty & generic |
Description
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Key trends
Similar companies
Eagle Pharmaceuticals Inc
NA
NA
Phibro Animal Health Corporation
NA
NA
Procaps Group SA
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email